Summary of Study ST000491

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench,, where it has been assigned Project ID PR000370. The data can be accessed directly via it's Project DOI: 10.21228/M87604 This work is supported by NIH grant, U2C- DK119886.


Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)
Study IDST000491
Study TitleSleep apnea and cardiovascular samples amino acid metabolites
Study SummarySleep apnea and cardiovascular samples amino acid metabolites
Mayo Clinic
LaboratoryMayo Clinic Metabolomics Resource Core
Last NamePak
First NameVictoria
Submit Date2016-10-14
Analysis Type DetailLC-MS
Release Date2018-10-10
Release Version1
Victoria Pak Victoria Pak application/zip

Select appropriate tab below to view additional metadata details:


Project ID:PR000370
Project DOI:doi: 10.21228/M87604
Project Title:Mayo Metabolomics Pilot and Feasibility Award: Mechanisms of sleep apnea and cardiovascular disease
Project Type:MS targeted analysis
Project Summary:Targeted Metabolic and Biological Markers of Sleepiness Symptoms in Sleep apnea and cardiovascular disease
Institute:Mayo Clinic
Laboratory:Mayo Clinic Metabolomics Resource Core
Last Name:Pak
First Name:Victoria


Subject ID:SU000512
Subject Type:Human
Subject Species:Homo sapiens
Taxonomy ID:9606
Species Group:Human


Subject type: Human; Subject species: Homo sapiens (Factor headings shown in green)

mb_sample_id local_sample_id Disease
SA025500ms5686-12cardiovascular disease
SA025501ms5686-11cardiovascular disease
SA025502ms5686-14cardiovascular disease
SA025503ms5686-16cardiovascular disease
SA025504ms5686-1cardiovascular disease
SA025505ms5686-10cardiovascular disease
SA025506ms5686-15cardiovascular disease
SA025507ms5686-13cardiovascular disease
SA025508ms5686-3cardiovascular disease
SA025509ms5686-9cardiovascular disease
SA025510ms5686-2cardiovascular disease
SA025511ms5686-4cardiovascular disease
SA025512ms5686-5cardiovascular disease
SA025513ms5686-8cardiovascular disease
SA025514ms5686-7cardiovascular disease
SA025515ms5686-6cardiovascular disease
SA025516ms5686-31sleep apnea
SA025517ms5686-30sleep apnea
SA025518ms5686-29sleep apnea
SA025519ms5686-32sleep apnea
SA025520ms5686-36sleep apnea
SA025521ms5686-28sleep apnea
SA025522ms5686-35sleep apnea
SA025523ms5686-34sleep apnea
SA025524ms5686-33sleep apnea
SA025525ms5686-19sleep apnea
SA025526ms5686-21sleep apnea
SA025527ms5686-20sleep apnea
SA025528ms5686-18sleep apnea
SA025529ms5686-17sleep apnea
SA025530ms5686-22sleep apnea
SA025531ms5686-23sleep apnea
SA025532ms5686-26sleep apnea
SA025533ms5686-25sleep apnea
SA025534ms5686-24sleep apnea
SA025535ms5686-27sleep apnea
Showing results 1 to 36 of 36


Collection ID:CO000506
Collection Summary:For the metabolic markers, 9 ml blood will be drawn into 3 EDTA tubes (3 ml each) and gently centrifuged at 4°C for 10 min; plasma aliquots were immediately frozen and stored at -80 °C; will be stored at -80ºC in the CTRC until all samples are collected and then sent to Mayo Clinic Metabolomics Core via LC-MS/MS for simultaneous detection and quantification of metabolites for analyses.
Sample Type:Blood


Treatment ID:TR000526
Treatment Summary:Recruitment of subjects will take place from the clinic population in collaboration with the Penn Sleep Center. Patients newly diagnosed with OSA will be solicited for via an overnight sleep study, which is general monitoring of sleep and variety of body functions during sleep. This includes brain (EEG), eye (EOG), and muscle activity and heart rhythm. The diagnosis of OSA will be established by full sleep study. First, the PI will screen for eligibility and obtain informed consent. We will assess height, weight, medical history, demographics. EDS will be measured subjectively on the night of enrollment in the study and determined using the Epworth Sleepiness Scale. The information regarding gender, BMI, smoking, age, medications (name/duration/frequency), and presence of comorbidities (e.g. hypertension, CVD defined by doctor diagnosis of myocardial infarction, stroke, or heart failure) will then be obtained via the electronic medical record. We will also ask subjects whether they exercise by asking participants the yes/no question: “During the past month, did you participate in any physical activities or exercises?” Second, the subject will undergo diagnostic PSG and we will enforce fasting prior to bedtime. Third, biological samples will be collected in the morning after the sleep study. Patients who have agreed to participate will undergo a blood draw (20 ml) and urine collection (30 ml) on the morning after PSG. Laboratory analysis of the biological samples will be conducted in collaboration with the Clinical Translation Research Center (CTRC). Finally, subjects will have 1 or 2 practice sessions with the PVT prior to administration of the task. PVT test will be conducted 3 times, at approximately 10:00, 12:00, and 14:00 and automatically scored. This will be done on the day after the sleep study.

Sample Preparation:

Sampleprep ID:SP000519
Sampleprep Summary:Amino Acid Panel

Combined analysis:

Analysis ID AN000757
Analysis type MS
Chromatography type Reversed phase
Chromatography system Waters Acquity
Column Waters Acquity BEH C18 (150 x 2.1mm,1.7um)
MS instrument type Triple quadrupole
MS instrument name Thermo Quantum Ultra
Units micromolar


Chromatography ID:CH000543
Instrument Name:Waters Acquity
Column Name:Waters Acquity BEH C18 (150 x 2.1mm,1.7um)
Chromatography Type:Reversed phase


MS ID:MS000669
Analysis ID:AN000757
Instrument Name:Thermo Quantum Ultra
Instrument Type:Triple quadrupole